SYDNEY, May 20, 2026, 05:07 AEST
CSL Ltd shares climbed on Tuesday, clawing back some of last week’s losses. The stock stayed under A$100 as investors watched for more evidence that the recent earnings reset has stabilized the biotech firm.
The ASX cash market wasn’t open at press time. Sydney’s regular session is from 09:59:45 to 16:00, so CSL traders are waiting for action in Wednesday’s opening auction and the first trades. Australian Securities Exchange
CSL finished the day at A$98.69, gaining 2.57%. Shares started at A$97.22. The stock remains 17.7% under its May 8 close, which was before CSL’s 90-day financial review was released. Intelligent Investor
Timing is a factor here. CSL isn’t riding a new product approval or an M&A story. The stock is trying to find a footing after it trimmed guidance, warned of hefty asset write-downs, and told the market that returns from its expansion plans will take more time.
Broad gains pushed the S&P/ASX 200 up 99.4 points, or 1.17%, to 8,604.7 on Tuesday. The All Ordinaries advanced 1.08%. The rally took some pressure off large caps that have been under pressure. Morningstar
CSL updated its guidance on May 11, forecasting fiscal 2026 revenue at about $15.2 billion and NPATA around $3.1 billion, both on a constant-currency basis. NPATA is net profit after tax before amortisation and certain one-off items, and the constant currency figure excludes changes from exchange rates for easier year-to-year comparisons.
CSL interim CEO Gordon Naylor said the company is “accelerating the execution” of its plan, but warned financial benefits will “take longer” to show. CSL flagged around $300 million of revenue hit from normalising U.S. immunoglobulin inventories. The company also listed about $200 million from softer albumin prices in China and about $150 million due to the Middle East conflict, slower HEMGENIX sales, and more competition in iron.
The size of the accounting write-down is still the bigger issue. CSL is looking at roughly $5 billion in extra non-cash, pre-tax impairments for FY26 and FY27. That’s in addition to the $1.5 billion already booked at the half-year. A non-cash impairment is an accounting drop in asset value. It cuts reported profit but doesn’t use up cash on its own.
CSL had no new major trading update on Tuesday. Its ASX announcements listed only an Appendix 3Y director-interest notice from May 18 and a financial update from May 11. CSL Limited
Cochlear climbed 1.98% to A$95.37 and ResMed’s ASX shares were up 1.99% at A$28.75, with both stocks moving higher along with CSL. That sent all three big healthcare stocks up on a strong session for the market. Investing.com Australia
The risks are still clear. If U.S. immunoglobulin inventory levels take longer to normalize, or albumin prices in China drop more, or iron market rivals get more aggressive, Tuesday’s gains might not last. Investors could start factoring in the chance of another guidance cut before the August numbers.
CSL is due to report its full-year results and final dividend on Aug. 18. The stock probably stays out of the defensive healthcare playbook for now and keeps acting like a bet on a turnaround that has to deliver. CSL Limited
